埃罗替尼为表皮生长因子受体酪氨酸激酶抑制剂,用作局部晚期或转移性非小细胞肺癌的二、三线治疗。埃罗替尼常见不良反应为痤疮样皮疹和腹泻。皮疹的发生率为61.7%～82.0%,主要分布在面部、颈部及躯干。接受埃罗替尼治疗的患者通常在治疗后1周左右发生皮疹,2～3周皮疹最严重,大多数患者的皮疹在第4周消退,但某些患者的皮疹会持续较长的时间。临床试验显示:皮疹和剂量相关;发生严重皮疹患者的生存期比轻度或未发生皮疹患者长。因此,皮疹可作为埃罗替尼有效治疗肺癌的预测指标。 Erlotinib is an epidermal growth factor receptor tyrosine kinase inhibitor used as second- and third-line therapy for locally advanced or metastatic non-small cell lung cancer. Common erlotinib adverse reactions were acne-like rashes and diarrhea. The incidence of rash was 61.7% ~ 82.0%, mainly in the face, neck and trunk. Patients receiving erlotinib usually have a rash about 1 week after treatment, the rash is most severe at 2 to 3 weeks, and the rash in most patients subsides at week 4, but the rash in some patients lasts longer. Clinical trials have shown that the rash is dose-related; patients with severe rashes have longer survival than those with mild or no rashes. Therefore, the rash can be used as a predictive indicator of erlotinib in the treatment of lung cancer.